Work

The Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus Inhibits the Activity of Cyclin-Cyclin-dependent Kinase Complex and Blocks S Phase Progression in Mammalian Cells

Year: 2006
Type: article
Abstract: Deregulation of the cell cycle is a common strategy employed by many DNA and RNA viruses to trap and exploit the host cell machinery toward their own benefit. In many coronaviruses, the nucleocapsid protein (N protein) has been shown to inhibit cell cycle progression although the mechanism behind this is poorly understood. The N protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) bears signature motifs for binding to cyclin and phosphorylation by cyclin-dependent kinase (CDK) and has recently been reported by us to get phosphorylated by the cyclin-CDK complex (Surjit, M., Kumar, R., Mishra, R. N., Reddy, M. K., Chow, V. T., and Lal, S. K. (2005) J. Virol. 79, 11476–11486). In the present study, we prove that the N protein of SARS-CoV can inhibit S phase progression in mammalian cell lines. N protein expression was found to directly inhibit the activity of the cyclin-CDK complex, resulting in hypophosphorylation of retinoblastoma protein with a concomitant down-regulation in E2F1-mediated transactivation. Coexpression of E2F1 under such conditions could restore the expression of S phase genes. Analysis of RXL and CDK phosphorylation mutant N protein identified the mechanism of inhibition of CDK4 and CDK2 activity to be different. Whereas N protein could directly bind to cyclin D and inhibit the activity of CDK4-cyclin D complex; inhibition of CDK2 activity appeared to be achieved in two different ways: indirectly by down-regulation of protein levels of CDK2, cyclin E, and cyclin A and by direct binding of N protein to CDK2-cyclin complex. Down-regulation of E2F1 targets was also observed in SARS-CoV-infected VeroE6 cells. These data suggest that the S phase inhibitory activity of the N protein may have major significance during viral pathogenesis. Deregulation of the cell cycle is a common strategy employed by many DNA and RNA viruses to trap and exploit the host cell machinery toward their own benefit. In many coronaviruses, the nucleocapsid protein (N protein) has been shown to inhibit cell cycle progression although the mechanism behind this is poorly understood. The N protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) bears signature motifs for binding to cyclin and phosphorylation by cyclin-dependent kinase (CDK) and has recently been reported by us to get phosphorylated by the cyclin-CDK complex (Surjit, M., Kumar, R., Mishra, R. N., Reddy, M. K., Chow, V. T., and Lal, S. K. (2005) J. Virol. 79, 11476–11486). In the present study, we prove that the N protein of SARS-CoV can inhibit S phase progression in mammalian cell lines. N protein expression was found to directly inhibit the activity of the cyclin-CDK complex, resulting in hypophosphorylation of retinoblastoma protein with a concomitant down-regulation in E2F1-mediated transactivation. Coexpression of E2F1 under such conditions could restore the expression of S phase genes. Analysis of RXL and CDK phosphorylation mutant N protein identified the mechanism of inhibition of CDK4 and CDK2 activity to be different. Whereas N protein could directly bind to cyclin D and inhibit the activity of CDK4-cyclin D complex; inhibition of CDK2 activity appeared to be achieved in two different ways: indirectly by down-regulation of protein levels of CDK2, cyclin E, and cyclin A and by direct binding of N protein to CDK2-cyclin complex. Down-regulation of E2F1 targets was also observed in SARS-CoV-infected VeroE6 cells. These data suggest that the S phase inhibitory activity of the N protein may have major significance during viral pathogenesis. Mitotic cells undergo repeated cycles of division in order to produce daughter cells, a process essential for the maintenance of tissue homeostasis. Different steps of a cell division event typically include the G1 phase (preparation for DNA synthesis), followed by the S phase (genome replication), the G2 phase (preparation for cell division), and the M phase (mitosis). One of the most critical phases during cell cycle progression is the S phase, since it involves precise duplication of the whole genome, which carries all genetic messages for the next generation. Any abnormality during the replication step or thereafter would be disastrous for the organism. Hence, cells employ multiple strategies to ensure accurate and error-free genome replication. First, cells synthesize adequate amounts of raw materials that would be utilized during the S phase; second, cells strategically employ multiple check points (in the form of inhibitory factors) to block the S phase progression should there be a hostile environment arising due to any intracellular or extracellular factors. The majority of the events during cell cycle progression are driven by enzymes called cyclin-dependent kinases (CDKs), 2The abbreviations used are: CDK, cyclin-dependent kinase; N protein, nucleocapsid protein; SARS, severe acute respiratory syndrome; CoV, coronavirus; BrdUrd, bromodeoxyuridine, Rb, retinoblastoma, FBS, fetal bovine serum; HA, hemagglutinin; FACS, fluorescence-activated cell sorting; CAT, chloramphenicol acetyltransferase; CKI, CDK inhibitor; ERK, extracellular signal-regulated kinase. which are dependent on a series of cyclins to remain catalytically active. Regulating the activity of these cyclin-CDK complexes constitutes the crux of cell cycle regulation, which remains under the scrutiny of inhibitors of CDK. On the other hand, this regulatory network has been an attractive target for pathogens to exploit the cellular machinery toward their benefit. For example, herpes simplex virus gene products ICP0 (1Hobbs II, W.E. DeLuca N.A. J. Virol. 1999; 73: 8245-8255Crossref PubMed J. Virol. 1999; 73: PubMed and G1 cell cycle and host gene expression during J. PubMed J. Virol. 1999; 73: PubMed and M. J. Virol. 1999; 73: PubMed of of virus J. PubMed of virus K. S. J. Virol. PubMed and of herpes virus J. Virol. PubMed have been shown to cell cycle progression the G1 has been that a G1 block may these pathogens in the cellular raw materials to their own genome or for a to their cycle and The of cell cycle virus to the virus and of bind to and J. PubMed J. Virol. PubMed S. PubMed which in the expression of to the inhibition of CDK2 and CDK4 the gene of herpes virus directly with and the activity of the complex J. Virol. PubMed the coronaviruses, the protein of virus has been shown to retinoblastoma and the levels of cell cycle the G1 phase K. S. J. Virol. PubMed The virus for severe acute respiratory is a recently which with the the of this virus in host cell cycle have recently shown that the nucleocapsid protein (N protein) of the SARS-CoV to the and bears signature motifs for binding to the cyclin and phosphorylation by the CDK, and we have it to be a of the cyclin-CDK complex M. R. J. Virol. PubMed in of the host cell cycle remains In this we that the N protein of the SARS-CoV to and the activity of the cyclin-CDK complex, resulting in down-regulation of the S phase gene products and inhibition of S phase identified the mechanism of inhibition to be different for G1 and phase In expression of the S phase gene products found to be in SARS-CoV-infected cells, the The significance of this during the of SARS-CoV is and has been M. S. J. PubMed RXL and and on by by the and and The mutant was by the the of the The of this was by The mutant was by a and was by cyclin that cyclin protein was a J. S. PubMed A and the for CDK2 and was a PubMed and mutant cyclin J. R. K. J. S. PubMed was a for and and and protein A was used to N protein was The was and other and and cells in with and fetal bovine with or or the cells with the For cells for in followed by with for the of cell cycle progression was by J. PubMed the and cells for in and with of for cells in and in with For amounts of protein with of the was followed by a with of protein The with and the protein was by the in by are of of and the The of of M. R. J. Virol. PubMed by in was a DNA of the DNA was the and the was by the machinery present in the The was a the The protein was of the was with amounts of and for and protein by followed by in or by In cell with kinase and with the with and of for for in of on and by in with The of DNA was for by the with cells with fetal bovine for the and in The was by J. PubMed and in and in followed by and in a for was the protein by followed by and with by the a and cells in with fetal under in a cells of cells that the was with J. J. Virol. PubMed S. V. J. Virol. PubMed was with SARS-CoV a in a of of J. Virol. PubMed with a virus of with of maintenance with fetal for the was and of maintenance was observed in cells. for and cells with of and for The cells to for and for to ensure of was to and SARS-CoV cells and was these by K. M. M. M. J. PubMed with of was with of and the under different conditions for for for and for followed by for the tissue for The for protein for in and followed by and of cyclin-CDK complex was by PubMed on the with cells with for and for in the of The was and cells with of of for The cells in and an was M. S. J. PubMed was observed and N protein expression was was with cells by a of the N the of in have that the N protein bears the for cyclin binding and phosphorylation by cyclin-dependent the N protein was found to be a of the cyclin-CDK complex M. R. J. Virol. PubMed the of signature motifs and phosphorylation by the CDK is a strategy employed by the N protein to the host cell cycle machinery toward by a to in of the cyclin-CDK complex. Hence, to check the of N protein expression on the kinase activity of different cyclin-CDK complex. to check the of different phases of cell cycle in and cells. For cells in the of for different to majority of the cell the phase and with to the cell cells to and the cell was to check the expression of different cyclin cyclin E, cyclin cyclin CDK2, and of the used for to check of different phases of cell cycle and for in phosphorylation to check the activity of cyclin cyclin E, cyclin and cyclin and M phase, was for the majority of the cells the phase, since cyclin E, cyclin or cyclin activity was of cyclin D activity was observed during In cells, all cyclins activity the which may be to the of in cells. the of FBS, activity of G1 and S phase cyclins and These us a the cell cycle of and cells, and the was followed in all of the on the cells with or with cells for and for different in order to different cyclin-CDK complexes during the of their in phosphorylation a was used to check the activity of the we the activity of CDK4-cyclin D complex. activity was found to be in N cells and all points ensure that an of protein was used in of the with CDK4 The a of the with to a a was to check the CDK4 activity in cells. was in CDK4 activity of cells in with cells the that the observed CDK4 inhibitory activity of the N protein is an of the we the activity of The inhibitory of the N protein on kinase activity appeared to be with that of CDK4 The the protein of a of the with to the expression of N protein The of cell cycle the points by cells to cell A of was cells, which protein expression cyclin-CDK cells with or for followed by with bovine for the of the with CDK4 cyclin D and and used for in phosphorylation A of the cell was with CDK4 or The In the of the in the and the and and cyclin and The of cell cycle and the the of cells in that cells and in A with cyclin D and of the with CDK4 or The was and with cyclin D A of the cell was with to check cells the and in phosphorylation was CDK2 cyclin and cyclin A of the cell with CDK4 or In the and CDK2, cyclin E, and cyclin A and the and The of cell cycle and the of cells in that cells and in with CDK2 and of the with cyclin and cyclin A A and cyclin and with CDK2 and In the the and cyclin E, cyclin and CDK2 protein and the and E, cells with the amounts of and or with bovine in phosphorylation was an of CDK4 or CDK2 CDK4 in phosphorylation in A a of the cell with CDK4 down-regulation of the CDK4-cyclin D activity may be a of of CDK4 with cyclin D or with the CDK4-cyclin D complex, we these in N cells. shown in of or N cell with cyclin D and with CDK4 or that there was in the of cyclin complex in N cells with cells. of cell with to ensure that amounts of used for observed that N protein expression could CDK4 activity the of the CDK4-cyclin D complex, we next N protein expression CDK2 activity in phosphorylation CDK2, cyclin E, and cyclin A that the N protein could inhibit CDK2 activity second, and and The an of the CDK4 protein, used a for this of of the also with to check the expression of N protein The of cell cycle the points by cells to we the of N protein expression on the of CDK2 and cyclin A complex. In to cyclin of the cyclin cyclin complex was found to be in cells and the of CDK2 protein used for was found to be in N cells Hence, it may be that expression of N protein the expression of cyclin E, cyclin and CDK2, resulting in of the complex. of the cell was with to protein amounts in the In order to ensure that the activity was a to the N protein, a was amounts of with or the N for followed by with for or CDK4 or CDK2 activity was by their to in in CDK4 and CDK2 activity was found to with amounts of the N protein expression retinoblastoma protein was used a of in the in phosphorylation to for a phosphorylation was by with CDK2 N cells These that the by the N protein of SARS-CoV was to this of the N S expression of the N protein could block the activity of G1 and S phase we next on the progression of the S or N cells for followed by with for of was by an is a that DNA and a of S phase shown in of cells The of in of cells may be to a of cells. N cells, cells that the majority of N cells to the S The data by the of cells different is shown in of N cells in S phase by of in a The N and the of E2F1 of the major target of CDK4 and CDK2 complex during G1 and G1 phase of the cell cycle is of by the activity of CDK4 and CDK2 has been shown to E2F1 the inhibitory activity of it to the of S phase genes. viral have been shown to inhibit E2F1 to cell cycle K. M. M. M. J. PubMed expression of the N protein could inhibit an for the of protein is of the phosphorylated by the phosphorylation in N cells The was and with to cellular a we the of with E2F1 and in or N cells different shown in and with E2F1 in N cells of and with E2F1 was in cells under protein was used a to ensure that amounts of protein used for of with E2F1 in N cells inhibition of E2F1 which would in expression of Hence, we the protein levels of of the E2F1 such cyclin and CDK2, by of cyclin and CDK2 found to be in N cells and was the on The that the observed was for CDK2 and was by of the with CDK4 which remains the or of the N protein of the with to check for in the of E2F1 activity was by the activity of an in N cells. A cyclin a or E2F1 was with or with the for followed by with for and activity was by of by activity of and a was N protein expression in inhibition of cyclin was observed in the mutant expression of E2F1 was to restore cyclin expression in N cells, the of E2F1 in cyclin activity of E2F1 and N protein was by of the with CDK2 kinase activity in and N cells. with different shown in the for and for followed by in phosphorylation of E2F1 could down-regulation of CDK2 activity in a of the with CDK2 levels of CDK2 to that of cells in cells of the with to check A of the is shown in the These suggest that the N protein E2F1 activity by resulting in expression of the S phase or of E2F1 is to the activity of the N The N of CDK of and inhibitors and are to be the major that cyclin-CDK activity under different by binding to the CDK or to the cyclin of different cyclins and to inhibition of their kinase Hence, expression of these is or protein is by a of or in order for to cell cycle many viral that host cell cycle are to the expression of these in order to block CDK activity J. Virol. PubMed to check N protein expression followed a or cells for followed by with for different with and A and and levels of and in N cells with to a to that CDK2 activity was in N cell used for of and protein, of the with which phosphorylation of the all points The was and with to ensure of the with to check expression of the N protein in these cells it was that the activity of the N protein is the of or of N CDK N protein has been shown to be a of cyclin-CDK complex and it bears the signature for binding to the cyclin which is in or inhibitors of the cyclin-CDK complex, such and PubMed the data that N inhibition of CDK activity CDK inhibitors we that N protein be the of by directly binding to the cyclin or it be a to of we N protein can inhibit CDK activity in an in phosphorylation One of cells in a with or with and in In a cells in a for with for or check CDK4 or CDK2 and in the was two and with amounts of or cell of CDK4 or CDK2 was to and with and an in phosphorylation was a shown in in the N CDK4 activity was with the CDK2 activity was in the N protein with although to a with to that of N protein expression was by of the with The was by (in and N protein in the in phosphorylation cell was and with and or and of N or of and of CDK4 or CDK2 was to and with and in phosphorylation was The of N in down-regulation of the activity of CDK4 and CDK2 a to check the observed is a of the N protein or is observed all of cyclin-CDK complex, we different of protein with cell of N protein in a of and the in phosphorylation was a inhibition of phosphorylation was observed in the of protein that the activity was to the N protein of since inhibition of CDK activity was observed the in and kinase we that it may be that the N protein to the cyclin-CDK complex and activity in a to that of In order to this a was to the RXL and motifs of the N The N Different to CDK4 and CDK2 an to prove the N protein a CDK we the and phosphorylation to and by the of the and their of these was by the protein with and The RXL mutant is mutant is shown and the the is for the of this mutant for expression in and cells. we an in phosphorylation CDK4 and CDK2 cell and different mutant N the and on their to inhibit CDK4 and CDK2 The mutant the mutant was in CDK4 activity with the N protein that the activity of the N protein was dependent on to bind to the cyclin The inhibition of the mutant that phosphorylation of the N protein by the cyclin-CDK complex be inhibitory the phosphorylation mutant was to bind to cyclin D and inhibit the mutant was to inhibit CDK4 of the was with CDK4 to check we the of N protein on CDK2 with different N protein for followed by with for was used for the in phosphorylation in the mutant could inhibit CDK2 activity the N protein, the and the activity of the with to check that the mechanism of CDK2 inhibition by the N protein is different that of CDK2 inhibition appeared to be of the of the RXL present in N the mutant the to inhibit the CDK2 we that it may be that the N protein a to the CDK2 In order to the we next the N protein could directly bind to cyclins the RXL in cyclin D or cyclin A and the N protein to the these cyclin and the N protein by an in and of was in of followed by the of of the and a with cyclin D or cyclin These in and with to check the N and the mutant of the N protein could bind to cyclin D the mutant binding The was and with cyclin D to check of all of the N protein was by of the in in the to the N protein was to with cyclin A protein we the of N protein with cyclin and cyclin complex by with different mutant for followed by a with and in with cyclin D and with or CDK4 The was and with cyclin D and of with cyclin complex, the mutant was to of the mutant with the cyclin complex appeared the and mutant of N we the of different N protein with the cyclin complex. with different for followed by a with and with to of cyclin A with the it was to check N by was for the and mutant N protein with the cyclin complex. the and mutant also to with the complex The was and with CDK2 of the was with to check The CDK2 was and to to check the expression of N protein These that the of the N protein with cyclin D it to directly inhibit CDK4 and since the mutant was to bind cyclin it the to inhibit cyclin kinase the to bind the cyclin D or cyclin complex and inhibition of CDK4 activity the of inhibition of CDK4 by the N since the mutant was in the CDK2 kinase activity and the mutant that the that the activity may be a of of the N protein with CDK2 was N to and CDK2 inhibition of CDK2 activity appeared to be in two ways: inhibition of E2F1 activity in expression of targets cyclin E, cyclin and second, the N protein be a to CDK2 The was due to the of N protein to inhibit the CDK2 activity in the to was by the of mutant N protein to inhibit the activity of or CDK2-cyclin A complex. The N protein the and expression was for and with for followed by in with or of or mutant N protein or of followed by the of of CDK2 and In phosphorylation was a the mutant could inhibit CDK2 the mutant was to this that the N protein CDK2 activity by directly binding to the complex, of other host of in the process could be In order to the we the of N protein to inhibit CDK2 activity cyclin A and of different cells cyclin A and CDK2 kinase in in and the resulting cyclin complex was on cyclin A protein by multiple in of cyclin A and CDK2 was by with complex was for CDK2 the cyclin complex found to be by their to or cyclin or catalytically In order to that CDK2 activity in the the cyclin complex on protein was for CDK2 activity in the of of protein and an of with of phosphorylation was CDK2-cyclin A complex to protein was in and with of or mutant N protein, and an in phosphorylation was a the mutant was of the CDK2 the or mutant this of the with CDK2 to check that the N protein could directly inhibit CDK2 activity of to CDK4 activity or the of other host factors. Down-regulation of E2F1 and of CDK2 in SARS-CoV-infected of the that N protein has the of CDK activity and S phase progression in mammalian cells. the was during a was we the protein of E2F1 targets in SARS-CoV-infected cells. cells with SARS-CoV or cells and and cell was under and with cyclin CDK2, and levels of cyclin A and CDK2 and in cells, the in of the with to check expression in the was used a these data suggest that the of N protein to inhibit cell cycle progression is a step during the of In this we to prove that the N protein of SARS-CoV S phase progression in mammalian cells. Down-regulation of the S phase gene expression and phosphorylation of a CDK2 in SARS-CoV-infected cells suggest the of N protein to be the of a process by which a viral protein the cell cycle viral have been shown to or the cell cycle in order to a for their For example, many viral gene products with cell cyclins and or their such and protein (1Hobbs II, W.E. DeLuca N.A. J. Virol. 1999; 73: 8245-8255Crossref PubMed J. PubMed J. Virol. PubMed S. PubMed J. 1999; PubMed S. J. Virol. PubMed R. J. J. PubMed J. S. J. J. Virol. PubMed J. Virol. PubMed of these cell cycle progression and cell in to the of target cells. On the other hand, many other viral gene such of herpes simplex and of and of cell cycle progression and the cells the G1 the viral gene products that in inhibition of CDK protein of has been shown to directly with CDK2-cyclin complex and kinase this was found to be by an in the protein of and to G1 J. Virol. PubMed in the present study, the N protein of SARS-CoV was found to with the cyclin-CDK complex and inhibit their the observed was of and since their protein in N cells. may be to the that for the of the G1 phase M. S. M. K. and we of protein which the expression of in the event of the observed was an of N protein and was in multiple for example, different N protein different on CDK2 and of E2F1 could the inhibitory of N protein in a and N protein could block the kinase activity of in cyclin-CDK complex. The mechanism of the CDK inhibitory by N protein appeared to be the viral CDK nucleocapsid multiple to inhibit CDK be to ensure that in the event of a of the to block CDK4 CDK2 activity be under that S phase progression is on the RXL to inhibit CDK4 activity and the to inhibit CDK2 N protein appeared to an to inhibit CDK2 kinase although mutant was to inhibit CDK4 activity in N cells, of inhibitory activity was by the mutant toward CDK2 kinase this inhibitory activity was observed in the CDK2 kinase mutant N protein was that this is of RXL and motifs of the N protein and is dependent on other host cellular factors. may be that the N protein also host to inhibit CDK2 a to inhibit CDK2 all of these in a protein, the virus may be to CDK4 and CDK2 critical in cell cycle of of these or the and E2F1 by Rb, E2F1-mediated of S phase cyclin E, cyclin DNA CDK2, K. M. J. PubMed PubMed M. 1999; PubMed PubMed is of the steps essential for S phase during G1 and S phase, CDK2 and targets for which is also essential for G1 to S phase M. 1999; PubMed 1999; PubMed CDK4 and CDK2 multiple to S phase Hence, by the of CDK4 and CDK2, the N protein the of S phase the significance of this during SARS-CoV remains to be it the virus and raw materials for replication of genome for and of to be in order to the of the the present of of the N protein by which the N protein be cell cycle during SARS-CoV for cyclin for the A J. R. for the cyclin and for the are also to for the and and M. for
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W2001039644
FWCI: 5.611
Cites: 36
Cited by: 221
Related to: 10